


PHARMACEUTICAL 2020

MUSTANG BIO INC. Rank 174 of 358







PHARMACEUTICAL 2020

MUSTANG BIO INC. Rank 174 of 358



The relative strengths and weaknesses of MUSTANG BIO INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MUSTANG BIO INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 66% points. The greatest weakness of MUSTANG BIO INC. is the variable Research and Development, reducing the Economic Capital Ratio by 36% points.

The company's Economic Capital Ratio, given in the ranking table, is 89%, being 53% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	63,063
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,771
Liabilities, Non-Current	1,843
Other Assets	10,382
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	12,179
Other Net Income	-504
Other Revenues	0
Property and Equipment	0
Research and Development	36,315
Selling, General and Administrative Expense	9,570

Output Variable	Value in 1000 USD
Assets	73,445
Liabilities	21,793
Expenses	45,885
Revenues	0
Stockholders Equity	51,652
Net Income	-46,389
Comprehensive Net Income	-46,389
Economic Capital Ratio	89%

